Table 2.
Aptamer targets with significantly different serum concentrations in the Rochester cohort.
| Targeta | Target protein description | Mean RFUb (Control) |
Mean RFU (FSHD) |
FCc | p-valued | Adjusted p-valuee |
|---|---|---|---|---|---|---|
| CK-MB | Creatine kinase M:Creatine kinase B heterodimer | 2,153.3 | 4,867.5 | 2.3 | 2.65E−05 | 5.99E−03 |
| CA- III | Carbonic anhydrase 3 | 2,687.2 | 6,040.8 | 2.2 | 3.21E−05 | 6.05E−03 |
| TCTP | Translationally-controlled tumor protein | 3,984.9 | 6,907.3 | 1.7 | 8.12E−05 | 1.02E−02 |
| CK-MM | Creatine kinase M-type | 1,108.8 | 2,006.3 | 1.8 | 2.84E−04 | 1.69E−02 |
| CSK | Tyrosine-protein kinase CSK | 1,018.7 | 1,612.0 | 1.6 | 2.37E−04 | 1.69E−02 |
| PDPK1 | 3-phosphoinositide-dependent protein kinase 1 | 776.5 | 1,478.3 | 1.9 | 2.37E−04 | 1.69E−02 |
| NUDCD3 | NudC domain-containing protein 3 | 550.5 | 2,059.8 | 3.7 | 6.76E−04 | 3.02E−02 |
| FER | Tyrosine-protein kinase Fer | 325.1 | 653.4 | 2.0 | 8.29E−04 | 3.02E−02 |
| NSF1C | NSFL1 cofactor p47 | 1,043.7 | 1,952.4 | 1.9 | 8.29E−04 | 3.02E−02 |
| DUS3 | Dual specificity protein phosphatase 3 | 1,000.4 | 2,009.8 | 2.0 | 7.46E−04 | 3.02E−02 |
| UFM1 | Ubiquitin-fold modifier 1 | 3,708.3 | 5,593.3 | 1.5 | 6.62E−04 | 3.02E−02 |
| SHC1 | SHC-transforming protein 1 | 8,151.0 | 15,477.8 | 1.9 | 8.29E−04 | 3.02E−02 |
| IF4G2 | Eukaryotic translation initiation factor 4 gamma 2 | 1,087.2 | 1,737.5 | 1.6 | 9.88E−04 | 3.38E−02 |
| C3b | Complement C3b | 4,002.6 | 6,241.6 | 1.6 | 1.97E−03 | 5.30E−02 |
| DRG-1 | Vacuolar sorting-associated protein VTA1 homolog | 14,957.0 | 28,488.9 | 1.9 | 2.36E−03 | 5.33E−02 |
| GPVI | Platelet glycoprotein VI | 10,462.9 | 16,710.3 | 1.6 | 2.36E−03 | 5.33E−02 |
| SBDS | Ribosome maturation protein SBDS | 1,796.2 | 2,894.3 | 1.6 | 2.03E−03 | 5.33E−02 |
| PSMA | Glutamate carboxypeptidase 2 | 2,917.7 | 4,791.0 | 1.6 | 2.55E−03 | 5.48E−02 |
| TNNI2 | Troponin I, fast skeletal muscle | 8,282.0 | 15,461.1 | 1.9 | 3.02E−03 | 5.48E−02 |
| CA-XIII | Carbonic anhydrase 13 | 3,102.6 | 7,303.8 | 2.4 | 2.63E−03 | 5.48E−02 |
| BTK | Tyrosine-protein kinase BTK | 1,483.7 | 3,241.0 | 2.2 | 3.02E−03 | 5.48E−02 |
a
Significant targets were defined as those having a FC ≥ 1.5 and p-value ≤ .005.
b
RFU = Relative fluorescence units.
c
FC = Fold change.
d
p-values are from the D-statistic generated with the Kruskal–Wallis test.
e
False discovery rate was determined by adjusting p-values for multiple testing using the formula of Benjamini and Hochberg.